{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:00:32Z","timestamp":1790384432011,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore potential therapeutic targets of MPM. Nucleoplasmin 2 (NPM2) is a molecular chaperone that binds histones and may play a key role in the development and progression of tumors. This study aimed to analyze the correlation between the expression level of NPM2 and the main clinicopathological characteristics and prognosis of MPM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ninety-two postoperative specimens from MPM patients following cytoreductive surgery were collected. Postoperative specimens were stained with immunohistochemistry. The expression level of NPM2 was quantitatively analyzed by QuPath-0.3.2 software. Univariate and multivariate analyses were conducted to investigate the correlation between NPM2 expression and other conventional clinicopathological characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 92 MPM patients, there were 47 males (48.9%) and 45 females (51.1%), with a median age of 56 (range: 24\u201373). There were 70 (76.0%) cases with loss of NPM2 protein expression, 11 (12.0%) cases with low expression, and 11 (12.0%) cases with high expression. Univariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was negatively correlated with the following three clinicopathological factors: completeness of cytoreduction (CC) score, vascular tumor emboli, and serious adverse events (SAEs) (all <jats:italic>P<\/jats:italic> &lt; 0.05). Multivariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was independently negatively correlated with the following two clinicopathological factors: CC score [odds ratio (OR) = 0.317, 95% <jats:italic>CI<\/jats:italic>: 0.317\u20130.959, <jats:italic>P<\/jats:italic> = 0.042] and vascular tumor emboli (<jats:italic>OR<\/jats:italic> = 0.092, 95% <jats:italic>CI<\/jats:italic> = 0.011\u20130.770, <jats:italic>P<\/jats:italic> = 0.028). Survival analysis showed that loss of NPM2 protein expression (negative vs. positive) was associated with poor prognosis of MPM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Loss of NPM2 expression is a potential immunohistochemical marker for MPM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-022-02811-y","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T04:02:57Z","timestamp":1666584177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases"],"prefix":"10.1186","volume":"20","author":[{"given":"He-liang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-ran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-dong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-mei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-6538","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"2811_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","volume":"20","author":"SH Moolgavkar","year":"2009","unstructured":"Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control. 2009;20:935\u201344. https:\/\/doi.org\/10.1007\/s10552-009-9328-9.","journal-title":"Cancer Causes Control"},{"key":"2811_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10:1240\u20132. https:\/\/doi.org\/10.1097\/JTO.0000000000000663.","journal-title":"J Thorac Oncol"},{"key":"2811_CR3","doi-asserted-by":"publisher","first-page":"195209","DOI":"10.1155\/2011\/195209","volume":"2011","author":"MS Lindstr\u00f6m","year":"2011","unstructured":"Lindstr\u00f6m MS. NPM1\/B23: a multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem Res Int. 2011;2011:195209. https:\/\/doi.org\/10.1155\/2011\/195209.","journal-title":"Biochem Res Int"},{"key":"2811_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12957-022-02604-3","volume":"20","author":"HL Wu","year":"2022","unstructured":"Wu HL, Yang ZR, Yan LJ, Su YD, Ma R, Li Y. NPM2 in malignant peritoneal mesothelioma: from basic tumor biology to clinical medicine. World J Surg Oncol. 2022;20:141. https:\/\/doi.org\/10.1186\/s12957-022-02604-3.","journal-title":"World J Surg Oncol"},{"key":"2811_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/02656736.2022.2066728","volume":"39","author":"YD Su","year":"2022","unstructured":"Su YD, Yang ZR, Li XB, Yu Y, Du XM, Li Y. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China. Int J Hyperth. 2022;39:706\u201312. https:\/\/doi.org\/10.1080\/02656736.2022.2066728.","journal-title":"Int J Hyperth"},{"key":"2811_CR6","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5.","journal-title":"Sci Rep"},{"key":"2811_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cdp.2006.10.008","volume":"30","author":"MJ Lim","year":"2006","unstructured":"Lim MJ, Wang XW. Nucleophosmin and human cancer. Cancer Detect Prev. 2006;30:481\u201390. https:\/\/doi.org\/10.1016\/j.cdp.2006.10.008.","journal-title":"Cancer Detect Prev"},{"key":"2811_CR8","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/leu.2009.124","volume":"23","author":"B Falini","year":"2009","unstructured":"Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23:1731\u201343. https:\/\/doi.org\/10.1038\/leu.2009.124.","journal-title":"Leukemia"},{"key":"2811_CR9","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1182\/blood-2005-11-4745","volume":"107","author":"B Falini","year":"2006","unstructured":"Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107:4514\u201323. https:\/\/doi.org\/10.1182\/blood-2005-11-4745.","journal-title":"Blood"},{"key":"2811_CR10","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2019004226","volume":"136","author":"B Falini","year":"2020","unstructured":"Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136:1707\u201321. https:\/\/doi.org\/10.1182\/blood.2019004226.","journal-title":"Blood"},{"key":"2811_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254\u201366. https:\/\/doi.org\/10.1056\/NEJMoa041974.","journal-title":"N Engl J Med"},{"key":"2811_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood-2010-08-299990","volume":"117","author":"B Falini","year":"2011","unstructured":"Falini B, Martell MP, Bolli N, Sportoletti P, Liso A, Tiacci E, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117:1109\u201320. https:\/\/doi.org\/10.1182\/blood-2010-08-299990.","journal-title":"Blood"},{"key":"2811_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"key":"2811_CR14","doi-asserted-by":"publisher","first-page":"e82136","DOI":"10.1371\/journal.pone.0082136","volume":"8","author":"A Ding","year":"2013","unstructured":"Ding A, Zhao W, Shi X, Yao R, Zhou F, Yue L, et al. Impact of NPM, TFF3 and TACC1 on the prognosis of patients with primary gastric cancer. PLoS One. 2013;8:e82136. https:\/\/doi.org\/10.1371\/journal.pone.0082136.","journal-title":"PLoS One"},{"key":"2811_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1423-0127-19-53","volume":"19","author":"Y Liu","year":"2012","unstructured":"Liu Y, Zhang F, Zhang XF, Qi LS, Yang L, Guo H, et al. Expression of nucleophosmin\/NPM1 correlates with migration and invasiveness of colon cancer cells. J Biomed Sci. 2012;19:53. https:\/\/doi.org\/10.1186\/1423-0127-19-53.","journal-title":"J Biomed Sci"},{"key":"2811_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.bbrc.2010.05.142","volume":"397","author":"A Pianta","year":"2010","unstructured":"Pianta A, Puppin C, Franzoni A, Fabbro D, Di Loreto C, Bulotta S, et al. Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun. 2010;397:499\u2013504. https:\/\/doi.org\/10.1016\/j.bbrc.2010.05.142.","journal-title":"Biochem Biophys Res Commun"},{"key":"2811_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1046\/j.1365-2141.2000.02285.x","volume":"110","author":"CA Westbrook","year":"2000","unstructured":"Westbrook CA, Hsu WT, Chyna B, Litvak D, Raza A, Horrigan SK. Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia. Br J Haematol. 2000;110:847\u201355. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.02285.x.","journal-title":"Br J Haematol"},{"key":"2811_CR18","doi-asserted-by":"publisher","first-page":"8874","DOI":"10.1128\/MCB.25.20.8874-8886.2005","volume":"25","author":"E Colombo","year":"2005","unstructured":"Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R, Marine JC, et al. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol. 2005;25:8874\u201386. https:\/\/doi.org\/10.1128\/MCB.25.20.8874-8886.2005.","journal-title":"Mol Cell Biol"},{"key":"2811_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nature03915","volume":"437","author":"S Grisendi","year":"2005","unstructured":"Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005;437:147\u201353. https:\/\/doi.org\/10.1038\/nature03915.","journal-title":"Nature"},{"key":"2811_CR20","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1182\/blood-2007-06-098251","volume":"111","author":"P Sportoletti","year":"2008","unstructured":"Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A, et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood. 2008;111:3859\u201362. https:\/\/doi.org\/10.1182\/blood-2007-06-098251.","journal-title":"Blood"},{"key":"2811_CR21","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ajpath.2011.04.009","volume":"179","author":"PR Karhemo","year":"2011","unstructured":"Karhemo PR, Rivinoja A, Lundin J, Hyv\u00f6nen M, Chernenko A, Lammi J, et al. An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer. Am J Pathol. 2011;179:1004\u201314. https:\/\/doi.org\/10.1016\/j.ajpath.2011.04.009.","journal-title":"Am J Pathol"},{"key":"2811_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3389\/fonc.2018.00675","volume":"8","author":"S Fujiwara","year":"2019","unstructured":"Fujiwara S, Nagai H, Jimbo H, Jimbo N, Tanaka T, Inoie M, et al. Gene expression and methylation analysis in melanomas and melanocytes from the same patient: loss of NPM2 expression is a potential immunohistochemical marker for melanoma. Front Oncol. 2019;8:675. https:\/\/doi.org\/10.3389\/fonc.2018.00675.","journal-title":"Front Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02811-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-022-02811-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02811-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T04:08:06Z","timestamp":1666584486000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-022-02811-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2811"],"URL":"https:\/\/doi.org\/10.1186\/s12957-022-02811-y","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethics Committee of Beijing Shijitan Hospital (2015-[28]). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The consent to participate was waived due to the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"350"}}